SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong1/7/2024 8:45:11 AM
1 Recommendation

Recommended By
Return to Sender

   of 8263
 
Top 8 stocks in ARK Innovation ETF that analysts like

Jan. 05, 2024 1:00 PM ET
By: Monica L. Correa, SA News Editor
8 Comments

Nastassia Samal/iStock via Getty Images

There are eight stocks in Cathie Wood’s ARK Innovation ETF (NYSEARCA: ARKK) that investors agree will offer more than 50% in gains during the next 12 months, according to Investor's Business Daily analysis of data from S&P Global Market Intelligence and MarketSmith.

Investor.com reported that the ARK Innovation ETF ( ARKK) closed the year with a 67.64% total return and was the most actively traded U.S. diversified ETF, topping the 55% of the Invesco Nasdaq 100 ETF ( QQQM).

In addition, analysts said that the 34 stocks in the ARK Innovation ETF ( ARKK) will gain an average of 30% in the next 12 months.

Analysts’ favorite ARK Innovation stocks, with their implied upside to 12-month price targets:

  • Verve Therapeutics ( VERV) - upside 229.2%
  • 2U ( TWOU) - upside 178%
  • Intellia Therapeutics ( NTLA) - upside 150.4%
  • Invitae ( NVTA) - upside 109%
  • Ginkgo Bioworks Holdings ( DNA) - upside 103.6%
  • Cerus ( CERS) - upside 91%
  • Beam Therapeutics ( BEAM) - upside 74.9%
  • Archer Aviation ( ACHR) - upside 52.4%
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext